Genetic profiling is gaining momentum as a tool for predicting limb risk in cardiometabolic disease. A study published in the European Heart Journal evaluated whether a polygenic risk score for peripheral artery disease improves risk assessment for limb complications. 

The analysis pooled genetic and clinical data from six TIMI trials. It included 68,816 adults with cardiometabolic conditions and used a median follow up period of 2.6 years. The study examined associations between the polygenic risk score and both existing peripheral artery disease and future major adverse limb events. These events included acute limb ischaemia, chronic limb threatening ischaemia, major amputation, or peripheral revascularization. 

In the results, 5,986 participants had peripheral artery disease at baseline. Higher polygenic risk scores aligned with greater odds of baseline disease. A total of 577 participants developed major adverse limb events during follow up. Higher scores also aligned with increased event risk. Adding the genetic score to clinical factors produced only modest gains in discrimination.

These findings show that genetic scores can enhance stratification even when traditional factors already explain much of the risk.